SkinBioTherapeutics (LON:SBTX) Stock Price Down 7.3% – Here’s What Happened

SkinBioTherapeutics plc (LON:SBTX) shares dropped 7.3% during mid-day trading on Monday . The stock traded as low as GBX 11 and last traded at GBX 11.25. 2,672,183 shares were traded during trading, a decline of 30% from the average session volume of 3,822,721 shares. The stock had previously closed at GBX 12.13.

SkinBioTherapeutics Stock Down 7.3%

The firm has a market cap of £29.16 million, a PE ratio of -36.29 and a beta of 0.12. The business’s 50 day moving average price is GBX 9.83 and its 200 day moving average price is GBX 12.16. The company has a debt-to-equity ratio of 11.77, a current ratio of 6.14 and a quick ratio of 10.01.

SkinBioTherapeutics (LON:SBTX) last posted its quarterly earnings data on Monday, June 8th. The company reported GBX (0.31) EPS for the quarter. The firm had revenue of GBX 217 million for the quarter. SkinBioTherapeutics had a negative return on equity of 5.25% and a negative net margin of 8.73%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.